Company Profile

LAURUS LABS LTD.

NSE : LAURUSLABSBSE : 540222ISIN CODE : INE947Q01028Industry : Pharmaceuticals & DrugsHouse : Private
BSE640.6536 (+5.95 % )
PREV CLOSE (Rs.) 604.65
OPEN PRICE (Rs.) 598.75
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 382359
TODAY'S LOW / HIGH (Rs.)588.20 648.00
52 WK LOW / HIGH (Rs.)162 697.75
NSE641.50 36.1 (+5.96 % )
PREV CLOSE(Rs.) 605.40
OPEN PRICE (Rs.) 600.00
BID PRICE (QTY) 641.50 (112390 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 8713131
TODAY'S LOW / HIGH(Rs.) 588.00 648.00
52 WK LOW / HIGH (Rs.)163 697.8

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.02
Dividend Yield(%) 0.31
TTM EPS (Rs.) 19.00
P/E Ratio 33.72
Book Value (Rs.) 54.59
Face Value (Rs.) 2
MCap (Rs. in Mn) 343774.32
Price/Earning (TTM) 28.09
Price/Sales (TTM) 6.85
Price/Book (MRQ) 11.74
PAT Margin (%) 20.05
ROCE (%) 38.60
Incorporation Year : 2005

Management Info :

M Venu Gopala Rao - Chairman - Managing Director

Registered Office :

Address : Plot No.21, J N Pharma City,Parawada, ,
Vishakhapatnam,
Andhra Pradesh-531021

Phone : 0891 3061222

Website : www.lauruslabs.com

Registrar's Details : K FIN Technologies Pvt Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE
NEWS More
19Jul07-19-2021$Laurus Labs informs about disclosures Laurus Labs informs about di

Laurus Labs has informed that the Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amansa Holdings & Amansa Investments.

The above information is a part of company’s filings submitted to BSE.

Laurus Labs has informed that the Exchange has received the dis..
02Jul07-02-2021$Laurus Labs gets license to manufacture, market 2-Deoxy-D-Glucose in India Laurus Labs gets license to

Laurus Labs has received the licence from Defence Research & Development Organisation (DRDO) to manufacture and market of 2- Deoxy-D-Glucose (2DG). 2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country.

Laurus Labs has already applied with CDSCO for emergency use authroisation (EUA) for 2DG. 

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs has received the licence from Defence Research &..
02Jul07-02-2021$Laurus Labs informs about press release Laurus Labs informs about pr
Laurus Labs has informed that the company is pleased to announce that it has received the licence from Defence Research & Development Organisation (DRDO) to manufacture and market of 2- Deoxy-D-Glucose (2DG). A press release to this extent is also enclosed.

The above information is a part of company’s filings submitted to BSE.

Laurus Labs has informed that the company is pleased to announc..
02Jul07-02-2021$Laurus Labs jumps on getting license to manufacture, market 2-Deoxy-D-Glucose in India Laurus Labs jumps on getting

Laurus Labs is currently trading at Rs. 676.90, up by 9.90 points or 1.48% from its previous closing of Rs. 667.00 on the BSE.

The scrip opened at Rs. 670.00 and has touched a high and low of Rs. 689.90 and Rs. 662.20 respectively. So far 342469 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 697.75 on 29-Jun-2021 and a 52 week low of Rs. 104.40 on 03-Jul-2020.

Last one week high and low of the scrip stood at Rs. 697.75 and Rs. 657.35 respectively. The current market cap of the company is Rs. 36271.64 crore.

The promoters holding in the company stood at 27.45%, while Institutions and Non-Institutions held 24.24% and 48.31% respectively.

Laurus Labs has received the licence from Defence Research & Development Organisation (DRDO) to manufacture and market of 2- Deoxy-D-Glucose (2DG). 2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country.

Laurus Labs has already applied with CDSCO for emergency use authroisation (EUA) for 2DG.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The company has grown consistently to become one of the leading manufacturers of APIs for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.

Laurus Labs is currently trading at Rs. 676.90, up by 9.90 poin..
30Apr04-30-2021$Laurus Labs reports around 3-fold jump in Q4 consolidated net profit Laurus Labs reports around 3

Laurus Labs has reported results for fourth quarter and year ended March 31, 2021.

The company has reported around 3-fold jump in its net profit at Rs 292.78 crore for the quarter under review as compared to Rs 112.53 crore for the same quarter in the previous year. Total income of the company increased by 69.04% at Rs 1,404.46 crore for Q4FY21 as compared Rs 830.85 crore for the corresponding quarter previous year.

On the consolidated basis, the company has reported around 3-fold jump in its net profit attributed to the owners at Rs 296.68 crore for the quarter under review as compared to Rs 110.15 crore for the same quarter in the previous year. Total income of the company increased by 68.46% at Rs 1,416.45 crore for Q4FY21 as compared Rs 840.82 crore for the corresponding quarter previous year.

For the year ended March 31, 2021, the company has reported around 4-fold jump in its net profit at Rs 956.11 crore as compared to Rs 267.05 crore for the previous year. Total income of the company increased by 71.09% at Rs 4,796.04 crore for year under review as compared to Rs 2,803.15 crore for year ended March 31, 2020.

For the year ended March 31, 2021, on the consolidated basis, the company has reported around 4-fold jump in its net profit attributed to the owners at Rs 983.58 crore as compared to Rs 255.27 crore for the previous year. Total income of the company increased by 70.46% at Rs 4,837.17 crore for year under review as compared to Rs 2,837.64 crore for year ended March 31, 2020.

Laurus Labs has reported results for fourth quarter and year en..
Financials More
Rs. in Millions
QTR Jun 21 ANNUAL 21
Net Profit2220.89561.1
Gross Profit 2901 12746.3
Operating Profit 3706.315371.9
Net Sales 1220647687.2
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Abbott India (BSE)
 19086.15 (4.92%)
M.Cap ( in Cr)
40556.74
Sanofi India (BSE)
 8367.90 (3.43%)
M.Cap ( in Cr)
19271.79
Alkem Laboratories (BSE)
 3454.55 (3.70%)
M.Cap ( in Cr)
41304.33
Sun Pharma Inds. (BSE)
 774.00 (10.06%)
M.Cap ( in Cr)
185708.53
Divi's Lab (BSE)
 4904.65 (1.20%)
M.Cap ( in Cr)
130203.05
Shareholding Pattern More
NON-INSTITUTION 47.01 %
PROMOTERS 27.3 %
MUTUAL FUNDS/UTI 2.32 %
FI/BANKS/INSURANCE 0.08 %
GOVERNMENT 0 %
FII 0 %
F & O Quotes